Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials (original) (raw)
Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy
LESLIE CITROME
Advances in Therapy, 2013
View PDFchevron_right
Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
Robert Litman
International journal of clinical practice, 2017
View PDFchevron_right
Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial
Gary Sachs
Journal of Affective Disorders, 2015
View PDFchevron_right
Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study
Victoria Burgess
American Journal of Psychiatry, 2019
View PDFchevron_right
An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression
Dr. István Laszlovszky
American Journal of Psychiatry, 2016
View PDFchevron_right
The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial
Dr. Jessica A . Giddens
2021
View PDFchevron_right
Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder
Dr. István Laszlovszky
The Journal of Clinical Psychiatry, 2014
View PDFchevron_right
Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies
Dr. István Laszlovszky
Journal of affective disorders, 2017
View PDFchevron_right
Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
Lakshmi Yatham
Frontiers in Psychiatry, 2021
View PDFchevron_right
Clinical potential of cariprazine in the treatment of acute mania
E. Timuçin Oral
View PDFchevron_right
Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder
Dr. István Laszlovszky
Journal of Affective Disorders, 2017
View PDFchevron_right
Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study
Mauricio Tohen
Bipolar Disorders, 2019
View PDFchevron_right
Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials
Frank Besag
CNS drugs, 2016
View PDFchevron_right
Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
Julie Passarell
Clinical and Translational Science, 2019
View PDFchevron_right
Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania
Vicent Llorca Bofí
Frontiers in Psychiatry
View PDFchevron_right
The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia
Pascal Goetghebeur
CNS Spectrums, 2022
View PDFchevron_right
The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study
Dr. István Laszlovszky
Journal of Affective Disorders, 2018
View PDFchevron_right
Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies
Dr. István Laszlovszky
European Neuropsychopharmacology, 2018
View PDFchevron_right
Cariprazine in Three Special Different Areas: A Real-World Experience
camilla gesi
Neuropsychiatric Disease and Treatment, 2021
View PDFchevron_right
Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
Marc Debelle
International clinical psychopharmacology, 2017
View PDFchevron_right
Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study
György Németh
CNS spectrums, 2017
View PDFchevron_right
Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
Mauricio Tohen
Drug Design, Development and Therapy, 2021
View PDFchevron_right
Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy
LESLIE CITROME
Advances in Therapy, 2013
View PDFchevron_right
Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
LESLIE CITROME
Neuropsychiatric Disease and Treatment, 2018
View PDFchevron_right
An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial
Dr. István Laszlovszky
Schizophrenia Research, 2014
View PDFchevron_right
Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review
Eashwar Kantemneni
Journal of Child and Adolescent Psychopharmacology, 2019
View PDFchevron_right
Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist
LESLIE CITROME
Clinical Schizophrenia & Related Psychoses, 2016
View PDFchevron_right
The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials
György Németh
CNS Spectrums, 2021
View PDFchevron_right
Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants
Dr. István Laszlovszky
The Journal of Clinical Psychiatry, 2016
View PDFchevron_right
The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
Dr. István Laszlovszky
BMC Psychiatry, 2017
View PDFchevron_right
Case Report: Long-Acting Oral Cariprazine
Matteo Preve
Frontiers in Psychiatry
View PDFchevron_right
Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
Stephen Volk
Psychopharmacology, 2017
View PDFchevron_right